Table 2.
Baseline characteristics for patients with T-LGLL.
| Variable | Total (%) (n=14) |
|---|---|
| Age at T-LGLL, mean (SD) | 62.8 (10.1) |
| Age at PCD diagnosis, mean (SD) | 63.6 (9.3) |
| Sex | |
| Male | 9 (64.3) |
| Female | 5 (35.7) |
| Race | |
| Caucasian | 13 (92.9) |
| African American | 1 (7.1) |
| Plasma Cell Dyscrasia | |
| MGUS | 8 (57.1) |
| MM | 4 (28.6) |
| Plasmacytosis | 2 (14.3) |
| Presenting Cytopenia at T-LGLL Diagnosis | |
| Neutropenia (ANC <1500) | 1 (7.1) |
| Anemia (Hgb <12) | 7 (50.0) |
| Both | 3 (21.4) |
| Unknown | 3 (21.4) |
| TCR V-Beta Positive at T-LGLL Diagnosis | |
| Yes | 8 (57.1) |
| No | 4 (28.6) |
| Unknown | 2 (14.3) |
| LGL Count (CD3CD8+) at Diagnosis | |
| <1,500 | 6 (42.9) |
| ≥1,500 | 5 (35.7) |
| Unknown | 3 (21.4) |
| LDH at T-LGLL Diagnosis | |
| ≤190 | 10 (71.4) |
| >190 | 3 (21.4) |
| Unknown | 1 (7.1) |
| Splenomegaly | |
| Yes | 4 (28.6) |
| No | 10 (71.4) |
| Associated Autoimmune Disease | |
| Rheumatoid arthritis | 5 (35.7) |
| ITP | 1 (7.1) |
| Anti-MAG neuropathy | 1 (7.1) |
| ANCA-associated vasculitis | 1 (7.1) |
| Cryoglobulinemia | 1 (7.1) |
| Anemia (Hgb <12) at PCD Diagnosis | |
| Yes | 9 (64.3) |
| No | 4 (28.6) |
| Unknown | 1 (7.1) |
| Bone Disease at PCD Diagnosis | |
| Yes | 2 (14.3) |
| No | 6 (42.9) |
| Unknown | 6 (42.9) |
| Creatinine at PCD Diagnosis | |
| <1.0 | 6 (42.9) |
| 1.0–1.5 | 4 (28.6) |
| 1.5–2.0 | 2 (14.3) |
| 2.0–2.5 | 0 (0.0) |
| 2.5–3.0 | 0 (0.0) |
| >3.0 | 1 (7.1) |
| Unknown | 1 (7.1) |
| Monoclonal Protein-Light Chain | |
| IgA-Unk | 1 (7.1) |
| IgG-K | 2 (14.3) |
| IgG-L | 3 (21.4) |
| IgM-K | 2 (14.3) |
| IgM-L | 1 (7.1) |
| N/A-K | 1 (7.1) |
| N/A-L | 2 (14.3) |
| None detected | 2 (14.3) |
| ISS Staging For PCD | |
| 1 | 2 (14.3) |
| 2 | 1 (7.1) |
| 3 | 1 (7.1) |
| N/A | 10 (71.4) |
| First-Line LGL Therapy | 10/14* (71.4) |
| Methotrexate | 5 (35.7) |
| Cyclophosphamide | 1 (7.1) |
| Cyclosporine | 3 (21.4) |
| CHOP | 1 (7.1) |
| First-Line PCD Therapy* | 3/14* (21.4) |
| Bortezomib/Lenalidomide/Dexamethasone | 2 (14.3) |
| Cyclophosphamide/Dexamethasone/Bortezomib | 1 (7.1) |
*One patient has not received treatment for either disease.